fenofibrate has been researched along with niacin in 69 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (4.35) | 18.7374 |
| 1990's | 7 (10.14) | 18.2507 |
| 2000's | 16 (23.19) | 29.6817 |
| 2010's | 41 (59.42) | 24.3611 |
| 2020's | 2 (2.90) | 2.80 |
| Authors | Studies |
|---|---|
| Ashford, A; Ashton, MJ; Loveless, AH; Riddell, D; Salmon, J; Stevenson, GV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Ruhn, G | 1 |
| Lorimer, AR; MacLean, J; Packard, CJ; Pringle, S; Shepherd, J; Simpson, H; Williamson, CM | 1 |
| Clavey, V; Fruchart, JC; Marzin, D; Olivier, P; Plancke, MO; Sauzieres, J | 1 |
| Franceschini, G; Paoletti, R; Sirtori, CR | 1 |
| Auwerx, J; Fruchart, JC; Staels, B; Van Tol, A | 1 |
| Bambauer, R; Müller, UA; Schiel, R | 1 |
| Farmer, JA; Gotto, AM | 1 |
| Sinzinger, H | 1 |
| Bays, HE; Dujovne, CA | 1 |
| Gylys, KH | 1 |
| Cottrell, DA; Falko, JM; Marshall, BJ | 1 |
| Dierkes, J; Luley, C; Westphal, S | 1 |
| Ascaso, JF; Felipe Pallardo, L; Fernández-Cruz, A; González Santos, P; Hernández Mijares, A; Mangas Rojas, A; Millán, J; Pedro-Botet, J; Pérez-Jiménez, F; Pía, G; Pintó, X; Plaza, I; Rubiés-Prat, J | 1 |
| Declercq, V; Moghadasian, MH; Moshtaghi-Kashanian, GR; Yeganeh, B | 1 |
| Nesto, RW | 1 |
| Hersberger, M; von Eckardstein, A | 1 |
| Balasubramanyam, A; Ballantyne, CM; Pownall, HJ; Samson, SL; Scott, LW; Sekhar, RV; Smith, EO | 1 |
| Cannon, CP | 1 |
| Robinson, JG | 1 |
| Alrasadi, K; Alwaili, K; Awan, Z; Genest, J; Hafiane, A; Krimbou, L; Ruel, I | 1 |
| Jones, PH | 1 |
| Cook, HT; Elkeles, RS; McLean, AG; Pavitt, DV; Richmond, W; Valabhji, J; Yee, MS | 1 |
| Ford, ES; Li, C; Mokdad, AH; Pearson, WS; Zhao, G | 1 |
| Alagona, P | 1 |
| Dunn, FL | 1 |
| Fabbrini, E; Klein, S; Korenblat, KM; Magkos, F; McCrea, J; Mohammed, BS; Patterson, BW | 1 |
| Phillips, W; Schaefer, S | 1 |
| Drakopoulou, M; Skoumas, I; Stefanadis, C; Toutouzas, K | 1 |
| Cho, SY; Chung, N; Jang, Y; Kang, SM; Kim, JY; Lee, SH; Park, S; Shim, WH; Wi, J | 1 |
| Balasubramanyam, A; Ballantyne, CM; Clark, P; Coraza, I; Cuevas-Sanchez, E; Giordano, TP; Iyer, D; Kamble, S; Patel, P; Pownall, HJ; Scott, LW; Sekhar, RV; Smith, EO; Taylor, AA | 1 |
| Fitch, K; Grinspoon, S | 1 |
| Dolgin, E | 1 |
| Sharpe, P | 1 |
| Bandgar, TR; Faruqui, AA | 1 |
| Prasad, V; Vandross, A | 1 |
| Balasubramanyam, A; Ballantyne, CM; Coraza, I; Gillard, BK; Nambi, P; Nambi, V; Pownall, HJ; Scott, LW; Wooten, JS | 1 |
| Elisaf, M; Kei, A; Liberopoulos, EN; Mikhailidis, DP | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Rizzo, M; Tellis, K; Tselepis, A | 1 |
| Elisaf, M; Kei, A; Liberopoulos, E; Tellis, C; Tselepis, A | 2 |
| Abt, M; Asztalos, B; Benghozi, R; Damonte, E; Davidson, WS; Gauthamadasa, K; Gylling, H; Kallend, D; Niesor, EJ; Rossomanno, S; Silva, RA; Suchankova, G | 1 |
| Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A | 1 |
| Kapoor, A; Kumar, S; Rai, H; Sinha, N; Tewari, S | 1 |
| Davidson, M; Singh, A | 1 |
| Dunbar, RL; Khera, AV; Qamar, A; Rader, DJ; Reilly, MP | 1 |
| Jacob, RF; Mason, RP | 1 |
| Amigó, N; Ascaso, JF; Blanco-Vaca, F; Cabré, A; Correig, X; Girona, J; Heras, M; Julve, J; Martínez-Hervás, S; Masana, L; Palomer, X; Plana, N; Quesada, H; Real, JT; Vázquez-Carrera, M | 1 |
| Cadden, JJ; Currier, JS; Dubé, MP; Fichtenbaum, CJ; Hodis, HN; Komarow, L; Overton, ET; Stein, JH | 1 |
| Adorni, MP; Benghozi, R; Calabresi, L; Damonte, E; Franceschini, G; Gomaraschi, M; Niesor, E; Ossoli, A; Veglia, F | 1 |
| Amigó, N; Blanco Vaca, F; Correig, X; Escolà-Gil, JC; Heras, M; Mallol, R; Martínez-Hervás, S; Masana, L; Plana, N; Yanes, Ó | 1 |
| Daka, A; Dimovski, A; Domazetovska, S; Kedev, S; Kuzmanovska, S; Mladenovska, K; Vavlukis, M | 1 |
| Handelsman, Y; Shapiro, MD | 1 |
| Jaffa, FM; Johnson, E; Kalyani, RR; Shubrook, JH; Skolnik, N | 1 |
| Gagne, JJ; Hampp, C; Houstoun, M; Marshall, JH; Reichman, ME; Toh, S | 1 |
| Hsiung, JT; Kleine, CE; Moradi, H; Park, C; Soohoo, M; Streja, DA; Streja, E | 1 |
| Preston Mason, R | 1 |
| Alshaikh, RA; El Maghraby, GM; Essa, EA | 1 |
| Abushanab, D; Ademi, Z; Al-Badriyeh, D; Bailey, C; Jaam, M; Liew, D; Marquina, C | 1 |
21 review(s) available for fenofibrate and niacin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Choosing the right lipid-regulating agent. A guide to selection.
Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Niacin; Triglycerides | 1996 |
[Antilipemic agents and atherothrombosis. Effects of antilipemic agents on blood platelet function, coagulation and fibrinolysis].
Topics: Anticholesteremic Agents; Antiporters; Arteriosclerosis; Bezafibrate; Blood Coagulation; Blood Coagulation Factors; Blood Platelets; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Fibrinolysis; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lovastatin; Niacin; Pravastatin; Risk Factors; Simvastatin; Thrombosis | 1998 |
Drug interactions of lipid-altering drugs.
Topics: Contraindications; Drug Interactions; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin; Probucol; Resins, Plant | 1998 |
Pharmacology department: pharmacologic approaches to abnormal blood lipids.
Topics: Anion Exchange Resins; Antioxidants; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Nursing Research; Patient Compliance | 2000 |
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Ezetimibe; Fenofibrate; Fish Oils; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertriglyceridemia; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Particle Size | 2003 |
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
Topics: Fenofibrate; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factors; Simvastatin | 2004 |
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Assessment | 2004 |
Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diet; Drug Therapy, Combination; Dyslipidemias; Exercise; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Life Style; Metabolic Syndrome; Niacin; Randomized Controlled Trials as Topic; Triglycerides | 2005 |
Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.
Topics: Animals; Atherosclerosis; ATP Binding Cassette Transporter 1; ATP-Binding Cassette Transporters; Biological Transport; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Estrogens; Fenofibrate; Fish Oils; Glycoproteins; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, HDL; Niacin; Scavenger Receptors, Class B; Testosterone | 2005 |
Combination therapy in the management of mixed dyslipidaemia.
Topics: Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Administration Routes; Drug Therapy, Combination; Dyslipidemias; Fatty Acids, Omega-3; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Metabolic Syndrome; Niacin; Randomized Controlled Trials as Topic | 2008 |
LDL reduction: how low should we go and is it safe?
Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coronary Artery Disease; Disease Progression; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Muscular Diseases; Niacin; Risk Factors; Stroke | 2008 |
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Metabolic Syndrome; Niacin; Risk Assessment; Risk Reduction Behavior; Vitamin B Complex | 2008 |
Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.
Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; Hypolipidemic Agents; Niacin; Practice Guidelines as Topic; Prognosis; Risk Factors; Risk Reduction Behavior | 2009 |
Management of dyslipidemia in people with type 2 diabetes mellitus.
Topics: Azetidines; Cholesterol, LDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dyslipidemias; Ezetimibe; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Male; Middle Aged; Niacin; Patient Education as Topic; Triglycerides | 2010 |
Advancing therapy for hypercholesterolemia.
Topics: Azetidines; Bile Acids and Salts; Carrier Proteins; Cholesterol; Cholesterol Ester Transfer Proteins; Cholesterol, LDL; Ezetimibe; Farnesyl-Diphosphate Farnesyltransferase; Fatty Acids, Omega-3; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Intestinal Absorption; Niacin | 2010 |
Combination therapy with statins: who benefits?
Topics: Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2014 |
TRIGLYCERIDES, ATHEROSCLEROSIS, AND CARDIOVASCULAR OUTCOME STUDIES: FOCUS ON OMEGA-3 FATTY ACIDS.
Topics: Atherosclerosis; Cardiovascular Diseases; Fatty Acids, Omega-3; Fenofibrate; Fibric Acids; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Niacin; Triglycerides | 2017 |
Precision Medicine and Personalized Management of Lipoprotein and Lipid Disorders in Chronic and End-Stage Kidney Disease.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Dyslipidemias; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Kidney Failure, Chronic; Muscular Diseases; Niacin; PCSK9 Inhibitors; Pharmacogenomic Variants; Practice Guidelines as Topic; Precision Medicine; Renal Dialysis; Renal Insufficiency, Chronic | 2018 |
New Insights into Mechanisms of Action for Omega-3 Fatty Acids in Atherothrombotic Cardiovascular Disease.
Topics: Atherosclerosis; Cell Membrane; Cholesterol, LDL; Coronary Thrombosis; Docosahexaenoic Acids; Eicosapentaenoic Acid; Endothelial Cells; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypertriglyceridemia; Niacin; Risk Factors; Triglycerides | 2019 |
A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Type 2; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Niacin; Proprotein Convertases; Secondary Prevention; Subtilisins | 2023 |
17 trial(s) available for fenofibrate and niacin
| Article | Year |
|---|---|
Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels.
Topics: Adipose Tissue; Animals; Apolipoprotein C-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins C; Bezafibrate; Cholesterol; Cholesterol, HDL; Clinical Trials as Topic; Clofibric Acid; Fenofibrate; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lipolysis; Lipoproteins, HDL; Niacin; Rats; Structure-Activity Relationship | 1983 |
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Enzyme-Linked Immunosorbent Assay; Female; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Longitudinal Studies; Lovastatin; Male; Middle Aged; Niacin; Pravastatin; Quality of Life | 1995 |
Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia.
Topics: Adult; Antiretroviral Therapy, Highly Active; Combined Modality Therapy; Diet, Fat-Restricted; Exercise; Female; Fenofibrate; HIV-Associated Lipodystrophy Syndrome; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin | 2006 |
Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.
Topics: Adult; Apolipoproteins B; Blood Glucose; Body Composition; Double-Blind Method; Fatty Acids, Nonesterified; Fatty Liver; Female; Fenofibrate; Glucose Clamp Technique; Humans; Hypolipidemic Agents; Insulin; Insulin Resistance; Kinetics; Lipoproteins, VLDL; Liver; Male; Middle Aged; Niacin; Obesity; Risk Factors; Triglycerides | 2010 |
Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.
Topics: Adult; Aged; Apolipoprotein A-I; Apolipoproteins B; Cholesterol, HDL; Female; Fenofibrate; Fibric Acids; Glucose; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Inflammation; Male; Middle Aged; Niacin | 2010 |
Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of "heart positive," a randomized, controlled trial.
Topics: Adiponectin; Adult; Aged; Anti-Retroviral Agents; Double-Blind Method; Dyslipidemias; Exercise; Female; Fenofibrate; HIV Seropositivity; Humans; Hypolipidemic Agents; Life Style; Male; Middle Aged; Niacin; Risk Reduction Behavior; Treatment Outcome; Triglycerides | 2011 |
Intensive lifestyle modification reduces Lp-PLA2 in dyslipidemic HIV/HAART patients.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Antiretroviral Therapy, Highly Active; Biomarkers; Chemokine CCL5; Combined Modality Therapy; Diet Therapy; Double-Blind Method; Drug Administration Schedule; Exercise Therapy; Female; Fenofibrate; HIV Infections; HIV-1; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Life Style; Linear Models; Male; Middle Aged; Niacin; Treatment Outcome | 2013 |
Comparison of switch to the highest dose of rosuvastatin vs. add-on nicotinic acid vs. add-on fenofibrate for mixed dyslipidaemia.
Topics: Cholesterol, HDL; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Middle Aged; Niacin; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
Effect of hypolipidemic treatment on emerging risk factors in mixed dyslipidemia: a randomized pilot trial.
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Adult; Aged; Apolipoproteins B; Atherosclerosis; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Middle Aged; Niacin; Pilot Projects; Prospective Studies; Pyrimidines; Risk Factors; Rosuvastatin Calcium; Sulfonamides; Time Factors | 2013 |
Lipid-modulating treatments for mixed dyslipidemia increase HDL-associated phospholipase A2 activity with differential effects on HDL subfractions.
Topics: Aged; Blood Chemical Analysis; Delayed-Action Preparations; Dose-Response Relationship, Drug; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Humans; Hypolipidemic Agents; Lipoproteins, HDL; Male; Middle Aged; Niacin; Phospholipases A2; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2013 |
Xanthophylls, phytosterols and pre-β1-HDL are differentially affected by fenofibrate and niacin HDL-raising in a cross-over study.
Topics: Apolipoprotein A-II; Cross-Over Studies; Dyslipidemias; Female; Fenofibrate; High-Density Lipoproteins, Pre-beta; Humans; Hypolipidemic Agents; Lutein; Male; Middle Aged; Niacin; Phytosterols; Xanthophylls; Zeaxanthins | 2013 |
Pharmacological measures to increase HDL-C among high risk isolated low HDL cases: a randomized study amongst north Indians.
Topics: Aged; Atorvastatin; Cholesterol, HDL; Coronary Disease; Female; Fenofibrate; Heptanoic Acids; Humans; India; Lipids; Male; Middle Aged; Niacin; Pyrroles; Risk Factors | 2013 |
Effect of switch to the highest dose of rosuvastatin versus add-on-statin fenofibrate versus add-on-statin nicotinic acid/laropiprant on oxidative stress markers in patients with mixed dyslipidemia.
Topics: Aged; Apolipoprotein B-100; Atorvastatin; Bilirubin; Biomarkers; Dinoprost; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Fluorobenzenes; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Lipoproteins, LDL; Male; Middle Aged; Niacin; Oxidative Stress; Prospective Studies; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Time Factors; Treatment Outcome; Uric Acid | 2014 |
Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
Topics: Aged; Apoptosis; Biomarkers; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Male; Niacin; Proprotein Convertase 9; Proprotein Convertases; Serine Endopeptidases; Treatment Outcome | 2015 |
Remarkable quantitative and qualitative differences in HDL after niacin or fenofibrate therapy in type 2 diabetic patients.
Topics: Adult; Aged; Antioxidants; Biomarkers; Cholesterol, HDL; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Fenofibrate; High-Density Lipoproteins, Pre-beta; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Indoles; Male; Metabolomics; Middle Aged; Niacin; Oxidants; Particle Size; Prospective Studies; Simvastatin; Spain; Time Factors; Treatment Outcome; Up-Regulation | 2015 |
Extended-Release Niacin Versus Fenofibrate in HIV-Infected Participants With Low High-Density Lipoprotein Cholesterol: Effects on Endothelial Function, Lipoproteins, and Inflammation.
Topics: Adult; Brachial Artery; C-Reactive Protein; Cholesterol, HDL; Delayed-Action Preparations; Dyslipidemias; Endothelium, Vascular; Female; Fenofibrate; HIV Infections; Humans; Inflammation; Lipoproteins; Male; Middle Aged; Niacin | 2015 |
Fenofibrate and extended-release niacin improve the endothelial protective effects of HDL in patients with metabolic syndrome.
Topics: Cells, Cultured; Cholesterol, HDL; Cross-Over Studies; Delayed-Action Preparations; Endothelial Cells; Female; Fenofibrate; Humans; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Niacin; Nitric Oxide Synthase Type III; Protective Agents; Vascular Cell Adhesion Molecule-1 | 2015 |
31 other study(ies) available for fenofibrate and niacin
| Article | Year |
|---|---|
Heterocyclic analogues of chlorcyclizine with potent hypolipidemic activity.
Topics: Animals; Body Weight; Chemical Phenomena; Chemistry; Cholesterol, Dietary; Eating; Hypolipidemic Agents; Indicators and Reagents; Male; Piperazine; Rats; Rats, Inbred Strains; Structure-Activity Relationship | 1984 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Relation between arteriographically diagnosed femoral atherosclerosis and serum lipids. Prevalence and treatment in hyperlipidaemic subjects.
Topics: Adult; Aged; Aorta, Abdominal; Aortic Aneurysm; Arteriosclerosis; Drug Therapy, Combination; Femoral Artery; Fenofibrate; Humans; Hyperlipidemias; Image Processing, Computer-Assisted; Lipids; Male; Middle Aged; Models, Cardiovascular; Niacin; Prevalence; Risk Factors; Tomography, X-Ray Computed | 1992 |
[Antilipemic agents and postprandial lipidemia].
Topics: Cholesterol; Chylomicrons; Coronary Artery Disease; Dietary Fats; Diterpenes; Female; Fenofibrate; Humans; Hyperlipidemias; Lipoproteins; Male; Metabolic Clearance Rate; Middle Aged; Niacin; Retinyl Esters; Triglycerides; Vitamin A | 1990 |
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofibrate; Gemfibrozil; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Mice; Mice, Inbred Strains; Niacin; Pentanoic Acids; Triglycerides | 1988 |
Effects of hypolipidemic drugs on the expression of genes involved in high density lipoprotein metabolism in the rat.
Topics: Actins; Animals; Apolipoproteins; Cholestyramine Resin; Clofibrate; Fenofibrate; Gene Expression Regulation; Hypolipidemic Agents; Intestinal Mucosa; Lipid Metabolism; Lipoproteins, HDL; Liver; Lovastatin; Male; Niacin; Probucol; Rats; Rats, Wistar; Simvastatin | 1996 |
Choice of lipid-regulating drugs.
Topics: Apolipoproteins; Arteriosclerosis; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Interactions; Drug Therapy, Combination; Fenofibrate; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hypolipidemic Agents; Muscular Diseases; Niacin; Triglycerides | 2001 |
Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Body Weight; Cholesterol; Cholesterol, HDL; Diet; Fenofibrate; Hypolipidemic Agents; Lipid Metabolism; Male; Mice; Mice, Knockout; Niacin; Phytosterols; Triglycerides | 2005 |
Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).
Topics: Adult; Aged; Atorvastatin; Cholesterol, HDL; Deficiency Diseases; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Male; Middle Aged; Niacin; Pilot Projects; Pyrroles; Severity of Illness Index | 2008 |
Changes in lipoprotein profile and urinary albumin excretion in familial LCAT deficiency with lipid lowering therapy.
Topics: Adult; Albumins; Calcium; Cholesterol; Coronary Vessels; Fenofibrate; Humans; Hypolipidemic Agents; Lecithin Cholesterol Acyltransferase Deficiency; Lipoprotein-X; Lipoproteins; Male; Niacin; Tomography, X-Ray Computed; Triglycerides | 2009 |
Hypertriglyceridemia and its pharmacologic treatment among US adults.
Topics: Adult; Female; Fenofibrate; Gemfibrozil; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Male; Middle Aged; Niacin; Nutrition Surveys; Prevalence; United States; Young Adult | 2009 |
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofibrate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Liver; Male; Middle Aged; Niacin | 2010 |
Niacin, fenofibrates increase benefits for statin users. These HDL- raising, triglyceride-lowering drugs beat out the use of additional LDL-lowering drugs.
Topics: Carotid Artery Diseases; Cholesterol, HDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Niacin; Ultrasonography | 2010 |
Therapy: HIV-associated dyslipidemia: the heart positive study.
Topics: Drug Therapy, Combination; Dyslipidemias; Exercise Therapy; Fenofibrate; Heart Diseases; HIV Infections; Humans; Niacin; Risk Reduction Behavior | 2011 |
Trial puts niacin--and cholesterol dogma--in the line of fire.
Topics: Cholesterol, HDL; Coronary Disease; Drug Approval; Fenofibrate; Humans; Hypolipidemic Agents; Niacin; United States; United States Food and Drug Administration | 2011 |
Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg).
Topics: Adult; Cholesterol, HDL; Drug Combinations; Drug Substitution; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Niacin; Treatment Outcome; Triglycerides | 2011 |
Managing dyslipidaemia: evolving role of combination therapy.
Topics: Atorvastatin; Azetidines; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fenofibrate; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins, HDL; Lipoproteins, LDL; Niacin; Pyrroles | 2011 |
Cardiovascular primary prevention: how high should we set the bar?
Topics: Anticholesteremic Agents; Azetidines; Biomarkers; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Drug Industry; Evidence-Based Medicine; Ezetimibe; Fenofibrate; Health Care Costs; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Mass Screening; Neoplasms; Niacin; Primary Prevention; Randomized Controlled Trials as Topic; Simvastatin | 2012 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones | 2014 |
Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism.
Topics: Antioxidants; Atorvastatin; Cholesterol, LDL; Eicosapentaenoic Acid; Fenofibrate; Gemfibrozil; Glucose; Heptanoic Acids; Lipid Peroxidation; Lipid Peroxides; Membrane Lipids; Membranes, Artificial; Niacin; Pyrroles | 2015 |
Lipoprotein hydrophobic core lipids are partially extruded to surface in smaller HDL: "Herniated" HDL, a common feature in diabetes.
Topics: Adult; Aged; Cardiovascular Diseases; Cholesterol, HDL; Diabetes Mellitus, Type 2; Female; Fenofibrate; Fluorescent Dyes; Humans; Indoles; Lipid Metabolism; Lipids; Magnetic Resonance Spectroscopy; Male; Microscopy, Atomic Force; Middle Aged; Niacin; Simvastatin; Surface Properties; Triglycerides | 2016 |
Effects of Rosuvastatin Versus Atorvastatin, Alone or in Combination, on Lipoprotein (a).
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol; Coronary Artery Disease; Drug Therapy, Combination; Female; Fenofibrate; Humans; Hypolipidemic Agents; Lipoprotein(a); Male; Middle Aged; Niacin; Prospective Studies; Rosuvastatin Calcium; Treatment Outcome; Triglycerides | 2016 |
Reducing CV risk in diabetes: An ADA update.
Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications; Creatinine; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, Drug; Drug Chronotherapy; Ezetimibe; Fenofibrate; Glucosides; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Hypolipidemic Agents; Life Style; Liraglutide; Metformin; Niacin; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Risk Reduction Behavior; Thiazolidinediones | 2017 |
Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cholesterol, HDL; Delayed-Action Preparations; Female; Fenofibrate; Follow-Up Studies; Gastrointestinal Hemorrhage; Humans; Hyperlipidemias; Hypolipidemic Agents; Incidence; Intracranial Hemorrhages; Male; Middle Aged; Niacin; United States; United States Food and Drug Administration; Young Adult | 2018 |
Preparation of stabilized submicron fenofibrate crystals on niacin as a hydrophilic hydrotropic carrier.
Topics: Administration, Oral; Biological Availability; Calorimetry, Differential Scanning; Chemistry, Pharmaceutical; Drug Carriers; Fenofibrate; Hydrogen Bonding; Hydrophobic and Hydrophilic Interactions; Hypolipidemic Agents; Microscopy, Electron, Scanning; Niacin; Particle Size; Solubility; Spectroscopy, Fourier Transform Infrared; X-Ray Diffraction | 2020 |